Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society

Pain Research and Management

Volumn 19, Issue 6, 2014, Pages 328-335

  De Moulin, D ^a   Boulanger, A ^b   Clark, A J ^c   Clarke, H ^d,e   Dao, T ^e   Finley, G A ^c   Furlan, A ^f   Gilron, I ^g,h   Gordon, A ^e,i   Morley Forster, P K ^a   Sessle, B J ^j,k   Squire, P ^l   Stinson, J ^m,n   Taenzer, P ^o   Velly, A ^p   Ware, M A ^q   Weinberg, E L ^g   Williamson, O D ^r  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g Department of Biomedical and Molecular Sciences ^*  (Canada)

^h QUEEN S UNIVERSITY   (Canada)

ⁱ Wasser Pain Management Centre   (Canada)

^j Faculty of Medicine   (Canada)

^k UNIVERSITY OF TORONTO   (Canada)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m HOSPITAL FOR SICK CHILDREN   (Canada)

ⁿ Peter Gilgan Centre for Research and Learning   (Canada)

^o UNIVERSITY OF CALGARY   (Canada)

^p MCGILL UNIVERSITY   (Canada)

^q MCGILL UNIVERSITY   (Canada)

^r FRASER HEALTH AUTHORITY   (Canada)

more..

Author keywords

Analgesic agents; Neuropathic pain; Randomized controlled trials

Indexed keywords

ANALGESIC AGENT;

ANALGESIA; CANADA; CHRONIC PAIN; CONSENSUS DEVELOPMENT; HUMAN; NEURALGIA; PRACTICE GUIDELINE; PROCEDURES;

ANALGESICS; CANADA; CHRONIC PAIN; HUMANS; NEURALGIA; PAIN MANAGEMENT;

EID: 84914158439     PISSN: 12036765     EISSN: None     Source Type: Journal    
DOI: 10.1155/2014/754693     Document Type: Article

References (82)

1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5.
2. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: A controlled comparison of people with and without diabetes. Diabet Med 2004;21:976-82.
3. Jung BF, Ahrendt GM, Oaklander AL, Dworkin RH. Neuropathic pain following breast cancer surgery: Proposed classification and research update. Pain 2003;104:1-13.
4. Foley KM. Opioids and chronic neuropathic pain. N Engl J Med 2003;348:1279-81.
5. Gilron I, Watson CP, Cahill CM, et al. Neuropathic pain: A practical guide for the clinician. CMAJ 2006;175:265-75.
6. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380-7.
7. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7:281-9.
8. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic neuropathy, postherpetic neuralgia and less commonly studied neuropathic pain conditions. Pain Pract 2008;8:45-56.
9. Hall GC, Morant SV, Carroll D, Gabriel ZL, McQuay HJ. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Fam Pract 2013;14:28.
10. Kautio AL, Haanpaa M, Kautianen H, Kalso E, Saarto T. Burden of chemotherapy-induced neuropathy - a cross-sectional study. Support Care Cancer 2011;19:1991-1998.
11. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain - Consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12:13-21.
12. Dworkin RH, Panarites CJ, Armstrong EP, Malone DC, Pham SV. Is treatment of postherpetic neuralgia in the community consistent with evidence-based recommendations? Pain 2012;153:869-75
13. Shekelle P, Eccles MP, Grimshaw JM, Woolf SH. When should clinical guidelines be updated? BMJ 2001;323:155-7.
14. Zakrzewska JM. Medical management of trigeminal neuropathic pains. Expert Opin Pharmacother 2010;11:1239-54.
15. Ashamn EJ, Gronseth GS. Level of evidence reviews - three years of progress. Neurology 2012;79-13-4.
16. Dworkin RH, Turk DC, Basch E, et al. Considerations for extrapolating evidence of acute and chronic pain analgesic efficacy. Pain 2011;152:1705-8.
17. Harden RN, Bruehl SP. Diagnostic criteria: The statistical derivation of the four criterion factors. In: Wilson P, Stanton-Hicks M, Harden RN, eds. CRPS: Current Diagnosis and Therapy (Progress in Pain Research and Management, Volume 32). Seattle: IASP Press, 2005:45-58.
18. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29-36.
19. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: Validation for use in clinic and postal research. J Pain 2005;6:149-58.
20. Cohen J. Statistical Power Analysis for the Behavioural Sciences. New York, San Francisco, London: Academic Press, 1988.
21. Taylor CP. The biology and pharmacology of calcium channel alpha2-delta proteins. CNS Drug Rev 2004;10:183-8.
22. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-23.
23. Gordh TE, Stubhaug A, Jensen TS, et al. Gabapentin in traumatic nerve injury pain: A randomized, double-blind, placebo-controlled, crossover, multi-centre study. Pain 2008;138:255-66.
24. Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007;110:2110-8.
25. Rintala DH, Holmes SA, Courtade D, et al. Comparison of the effectiveness of amitriptryline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil 2007;88:1547-60.
26. Smith DG, Ehde DM, Hanley MA, et al. Efficacy of gabapentin in treating chronic phantom limb and residual limb pain. J Rehabil Res Dev 2005;42:645-54.
27. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathy pain. Pain 2010;150:573-81.
28. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy. Neurology 2011:1-8.
29. Siddall PJ, Cousins MJ, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: A placebocontrolled trial. Neurology 2006;67:1792-800.
30. Vranken JH, Dijkgraaf MG, Kruis MR, et al. Pregabalin in patients with central neuropathic pain: A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2008;136:150-7.
31. Baron R, Freynhagen R, Tolle TR, et al. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 2010;150:420-7.
32. Philip R, Huffman C, Toth C, et al. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: A randomized withdrawal trial. Clin J Pain 2014;30:379-90.
33. Kim JS, Bashford G, Murphy TK, et al. Safety and efficacy of pregabalin in patients with central post-stroke pain. Pain 2011;152:1018-23.
34. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence-based proposal. Pain 2005;118:289-305.
35. Lavoie Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function and quality of life among patients with chemotherapy-induced painful peripheral neuropathy. JAMA 2013;309:1359-67.
36. Vranken JH, Hollmann MW, van der Vegt MH, et al. Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: A randomized, double-blind, placebo-controlled trial. Pain 2011;152:267-73.
37. Rowbotham MC, Goli V, Junz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Pain 2004;100:697-706. (Erratum in 2005;113:248).
38. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: A randomized, controlled trial. Neurology 2003;60:1284-9.
39. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis 2001;3:53-62.
40. Abramowicz M. Tramadol - a new oral analgesic. Med Lett Drugs Ther 1993;37:59-62.
41. Smith AB, Ravikumar TS, Kamin M, et al. Combination tramadol plus acetaminophen for postsurgical pain. Am J Surg 2004;187:521-7.
42. Hollingshead J, Duhmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst Rev 2006;(3):CD003726.
43. Furlan AD, Chaparro LE, Irvin E, Mailis-Gagnon A. A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. Pain Res Manag 2011;16:337-51.
44. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomized double-blind placebo-controlled crossover trial. BMJ 2004;329:253.
45. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-9.
46. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain: A systematic review of randomized trials. Br J Clin Pharmacol 2011;72:735044.
47. Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain 2012;153:2073-82.
48. Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992;52:547-52.
49. Sindrup SH, Cram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42:135-44.
50. Otto M, Bach FW, Jensen TS, Brosen K, Sindrup SH. Escitalopram in painful polyneuropathy: A randomized, placebo-controlled, crossover trial Pain 2008;139:275-83.
51. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-6.
52. Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 1997;33:454-71.
53. Wiffen PJ, Derry S, Moore RA. Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev 2011;(2):CD006044.
54. Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012;(2):CD009318.
55. Gorman A, Elliott K, Inturrisi C. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-Daspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 1997;223:5-8.
56. Morley JD, Bridson J, Nash TP, et al. Low dose methadone has an analgesic effect in neuropathic pain: A double-blind randomized controlled crossover trial. Palliat Med 2003;17:576-87.
57. Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manag 2003;8:149-54.
58. Moulin DE, Palma D, Watling C, Schulz V. Methadone in the management of intractable neuropathic noncancer pain. Can J Neurol Sci 2005;32:340-3.
59. Lynch M. A review of the use of methadone for the treatment of chronic noncancer pain. Pain Res Manag 2005;10:133-44.
60. Gammaaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother 2002;36:236-40.
61. Cheville AL, Sloan JA, Northfelt DW, et al. Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: A phase III double-blind crossover study (N01CB). Support Care Cancer 2009;17:451-60.
62. Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain 2008;24:51-5.
63. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011;27:151-62.
64. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2012;(9):CD010111.
65. Derry S, Rice, AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2013;(2):CD007393.
66. Yuan R-Y, Sheu J-J, Yu J-M, et al. Botulinum toxin for diabetic neuropathic pain. Neurology 2009;72:1473-8.
67. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurology 2008;64:274-83.
68. Gilron I, Jensen TS, Dickenson AH. Combination pharmacotherapy for management of chronic pain: From bench to bedside. Lancet Neurol 2013;12:1084-95.
69. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev 2012(7):CD008943.
70. Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: High-dose monotherapy or their combination? The "COMBO-DN study" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 2013;154:2616-25.
71. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217-27.
72. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: An overview of recent guidelines. Amer J Med 2009;122(10A):S22-S32.
73. Mao J. Opioid-induced abnormal pain sensitivity: Implications in clinical opioid therapy. Pain 2002:100:213-7.
74. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002;3:377-84.
75. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain 2008;9:28-36.
76. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviours? A structured evidence-based review. Pain Med 2008;9:444-59.
77. National Opioid Use Guideline Group (NOUGG). Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. (Accessed September 2013).
78. Teasell RW, Mehta W, Aubut JL, et al. A systematic review of pharmacologic treatments of pain after spinal cord injury. Arch Phys Med Rehabil 2010;91:816-31.
79. Leijon G. Boivie J. Central post-stroke pain - a controlled trial of amitriptyline and carbamazepine. Pain 1989;36:27-36.
80. Tremont-Lukats IW, Challapalli V, McNicol ED, et al. Systemic administration of local anesthetics to relieve neuropathic pain: A systematic review and meta-analysis. Anesth Analg 2005;101:1738-49.
81. Mailis A, Taenzer P. Evidence-based guideline for neuropathic pain interventional treatments: Spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks. Pain Res Manag 2012;17:150-8.
82. Dworkin RH, O'Connor AB, Kent J, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain 2013;54:2249-61.